9-tert-Butyl-9H-purin-6-ylamine | 127820-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-tert-Butyl-9H-purin-6-ylamine
• 英文别名: 9-Tert-butylpurin-6-amine
• CAS: 127820-12-6
• 化学式: C₉H₁₃N₅
• 分子量: 191.236
• InChiKey: LDNJSJPOGUUDGV-UHFFFAOYSA-N

物化性质

• 沸点：
  373.4±45.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-tert-Butyl-pyrimidine-4,5,6-triamine; compound with sulfuric acid 、 formamide 以33%的产率得到9-tert-Butyl-9H-purin-6-ylamine
  参考文献：
  名称：

  嘌呤衍生物作为人红细胞膜磷脂酰肌醇4-激酶的竞争性抑制剂。

  摘要：

  在一系列嘌呤衍生物和类似物中，已经研究了获得有效的，可穿透细胞的人红细胞PI 4-激酶抑制剂（相对于ATP具有竞争性）的可能性。嘌呤核对于结合到ATP位点不是必不可少的，但具有合成易接近其衍生物的优势。发现嘌呤中的最佳取代方式是6-位的电子释放取代基（例如氨基，如腺嘌呤1），在8位或最好在9位是紧密的亲脂基团，表明N-1孤对的重要性以及8和9取代基对结合的疏水作用。合成的最有效的抑制剂是9-环己基腺嘌呤（54），其表观Ki值为3.7 microM。

  DOI：

  10.1021/jm00170a005

文献信息

• Nucleoside and Nucleotide Analogues with Quaternary Carbon Centers and Methods of Use
  申请人：Guindon Yvan

  公开号：US20100093737A1

  公开（公告）日：2010-04-15

  The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3′ position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses. Thus, the present invention also comprising pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit viruses or tumors and treat, prevent, or inhibit the foregoing diseases.

  本发明包括用作抗病毒或抗肿瘤剂的化合物。这些化合物包括含有四氢呋喃基或四氢噻吩基的核苷酸类似物，在3'位置具有季铵中心。核苷酸类似物可用于抑制癌症或病毒。因此，本发明的化合物对于治疗、预防、和/或抑制与癌症和病毒相关疾病或状况是有用的。因此，本发明还包括包含这些化合物的药物制剂以及使用这些化合物和制剂来抑制病毒或肿瘤，以及治疗、预防或抑制前述疾病的方法。
• [EN] TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION<br/>[FR] TECHNOLOGIES UTILES POUR LA PRÉPARATION D'OLIGONUCLÉOTIDES
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2020191252A1

  公开（公告）日：2020-09-24

  Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.

  除其他事项外，本公开提供了寡核苷酸制备技术，特别是手性控制的寡核苷酸制备技术，这些技术大大提高了粗品纯度和产量，并显著降低了制造成本。
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS OLIGONUCLÉOTIDIQUES ET MÉTHODES ASSOCIÉES
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2019032612A1

  公开（公告）日：2019-02-14

  Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders.

  本公开提供寡核苷酸、组合物及其方法等内容。本公开涵盖了对寡核苷酸的结构元素（如碱基序列、化学修饰（例如糖、碱基和/或核苷酸间连接的修饰）或其模式、与额外化学基团的结合以及/或立体化学[例如骨架手性中心的立体化学（手性核苷酸间连接）]及/或其模式等）的认识，这些因素可能对寡核苷酸的性质和活性（例如敲低能力、稳定性、传递等）产生重要影响。在某些实施例中，寡核苷酸降低C9orf72基因的表达、活性和/或水平，包括但不限于包含重复扩展或其基因产物的基因。在某些实施例中，本公开提供使用所提供的寡核苷酸组合物治疗疾病的方法，例如治疗C9orf72相关疾病。
• LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF
  申请人：ADURO BIOTECH, INC.

  公开号：US20190185511A1

  公开（公告）日：2019-06-20

  The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2′, 4′ locked nucleic acids within the cyclic dinucleotide.

  本发明提供了高活性的锁定核酸环二核苷酸（LNA-CDN）免疫刺激剂，通过细胞质受体STING（干扰素基因刺激剂）激活DCs。具体而言，本发明的LNA-CDNs以一种组合物的形式提供，该组合物包括一种或多种诱导人类STING依赖型I型干扰素产生的环二核苷酸，其中组合物中的环二核苷酸至少有一个2′, 4′锁定核酸。
• PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID
  申请人：Lee Jong-Ook

  公开号：US20110178031A1

  公开（公告）日：2011-07-21

  The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

  本发明提供了一类新型的肽核酸衍生物，它们具有良好的细胞穿透性和对核酸的强结合亲和力。